By Sriparna Roy Sept 16 (Reuters) - Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis ...

Novartis (NVS) has discontinued the development of VHB937/lifonebart, an experimental therapy for a fatal nervous system disease known as amyotrophic lateral sclerosis, following a mid-stage trial ...

Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis (ALS) program after flunking a phase 2 ...

Axoltis Pharma announced today that its phase 2 trial for amyotrophic lateral sclerosis (ALS) has missed its primary endpoint ...

A new study published in Scientific Reports indicates that amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have an extremely high geographic association, even after controlling for ...

Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env ...

In people with amyotrophic lateral sclerosis (ALS), changes in neurons appear to activate immune cells. Lowering the inflammation could reduce the symptoms of the disease, according to a study led by ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

Novartis AG halted development of an experimental drug it hoped would treat amyotrophic lateral sclerosis, or Lou Gehrig’s ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects neurons in the brain and spinal cord causing loss of muscle control. Scientists have now suggested a potential ...